SCHEMBL15467504

SCHEMBL15467504

O=C1CNCc2c1ccc1ccccc21

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 3/20 0.46
HPGD P15428 3/20 0.46
CYP2C19 P33261 3/20 0.46
ALDH1A1 P00352 3/20 0.46
KDM4E B2RXH2 2/20 0.46
HTT P42858 1/20 0.46
CDK5 Q00535 1/20 0.46
CDK5R1 Q15078 1/20 0.46
NCOA1 Q15788 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
NCOA3 Q9Y6Q9 1/20 0.46
LMNA P02545 2/20 0.42
DNMT1 P26358 1/20 0.41
HSD17B10 Q99714 2/20 0.40
CYP2C9 P11712 2/20 0.40
GLA P06280 1/20 0.40
SIRT1 Q96EB6 1/20 0.40
CYP19A1 P11511 1/20 0.39
PAX8 Q06710 1/20 0.38
CYP2A6 P11509 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL246939 0.76 CDK5 (0.55) CYP1A2HPGDCYP2C19ALDH1A1KDM4E
SCHEMBL31069634 0.76 CDK5 (0.55) CYP1A2HPGDCYP2C19ALDH1A1KDM4E
SCHEMBL8359592 0.76 HPGD (0.51) CYP1A2HPGDCYP2C19ALDH1A1KDM4E
SCHEMBL4239276 0.74 ALDH1A1 (0.45) CYP1A2HPGDCYP2C19ALDH1A1KDM4E
SCHEMBL1938502 0.73 LMNA (0.46) ALDH1A1LMNAHSD17B10CYP2A6TSHR
SCHEMBL28265960 0.73 HPGD (0.44) CYP1A2HPGDCYP2C19ALDH1A1KDM4E
SCHEMBL7413330 0.73 BRD4 (0.48) CYP1A2HPGDCYP2C19ALDH1A1KDM4E
SCHEMBL9181184 0.69 KDM4E (0.49) CYP1A2HPGDCYP2C19ALDH1A1KDM4E
SCHEMBL29862069 0.69 KDM4E (0.49) CYP1A2HPGDCYP2C19ALDH1A1KDM4E
SCHEMBL9094448 0.69 LMNA (0.40) CYP1A2HPGDCYP2C19ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8946260-B2 17α-hydroxylase/C17,20-lyase inhibitors NOVARTIS AG (CH) 2015-02-03 US disclosed
US-20140045872-A1 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS NOVARTIS AG (CH) 2014-02-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140045872-A1 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS CYP17A1, CYP21A2, HSD17B1 CYP1A2 49/4885HPGD 200/4885CYP2C19 78/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.